Beclometasone hydrofluoroalkane inhalation - 3M

Drug Profile

Beclometasone hydrofluoroalkane inhalation - 3M

Alternative Names: Beclometasone dipropionate hydrofluoroalkane inhalation - 3M; Beclometasone HFA inhalation - 3M; Beclometasone pressurised metered-dose inhalation - 3M; Beclomethasone breath-activated inhalation - 3M; Beclomethasone dipropionate HFA - 3M; Beclomethasone dipropionate hydrofluoroalkane inhalation - 3M; Beclomethasone HFA inhalation - 3M; Beclomethasone hydrofluoroalkane inhalation - 3M; HFA-134a BDP; Hydrofluoroalkane-134a beclomethasone dipropionate; Junik; Nexxair®; Qvar; Qvar Autohaler; Qvar BAI; Qvar Easi-Breathe; Qvar MDI; Qvar RediHaler; Qvarspray; Ventolair

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer 3M Pharmaceuticals; Teva Branded Pharmaceutical Products R&D
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 16 Feb 2018 Launched for Asthma (In adolescents, In children, In adults) in USA (Inhalation; 40µg; QVAR® RediHaler™)
  • 16 Feb 2018 Launched for Asthma (In adolescents, In children, In adults) in USA (Inhalation; 80µg; QVAR® RediHaler™)
  • 16 Feb 2018 Withdrawn for Asthma (In children) in USA (Inhalation; QVAR® MDI)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top